Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions

• Published in: The European respiratory journal Vol. 21; no. 5; pp. 799 - 803
• Main Authors: Buttner, C, Lun, A, Splettstoesser, T, Kunkel, G, Renz, H
• Format: Journal Article
• Language: English
• Published: Leeds Eur Respiratory Soc 01.05.2003; Maney
• Subjects: Adult; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized; Asthma - drug therapy; Biological and medical sciences; Blood Proteins - analysis; Blood Proteins - immunology; Double-Blind Method; Eosinophil Granule Proteins; Eosinophils - immunology; Female; Humans; Interleukin-5 - immunology; Lymphocyte Activation - drug effects; Lymphocyte Activation - physiology; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Respiratory system; Ribonucleases; T-Lymphocytes - immunology; Immune response; Respiratory disease; Treatment efficiency; Cytokine; Monoclonal antibody; Mepolizumab; Eosinophil; Asthma; Immunomodulator; Chemotherapy; Interleukin 5; Treatment; Immunotherapy; T-Lymphocyte; Asthma eosinophils interleukin-5 lymphocytes treatment; Obstructive pulmonary disease; Mechanism of action

Influx of eosinophils in airway mucosa and airway lumen is a hallmark of bronchial asthma. In-vitro data and animal studies indicate that the T-helper (Th) type-2 cell cytokine, interleukin (IL)-5, plays an important role in eosinophil maturation, differentiation, recruitment, and survival. The obje...